Abbott Laboratories announced Monday it is ramping up production of its infant formula Similac at its Columbus facility amid a nationwide shortage while the company's main production facility in Michigan remains closed over sanitation safety concerns.
The Chicago-based company said in a release it has “prioritized infant formula production” at its Columbus Abbott Nutrition facility, converting other manufacturing lines into manufacturing its Similac “ready-to-feed” baby formula.
An Abbott spokesperson could not immediately be reached Monday for additional details.
Please select this link to read the complete article from Columbus CEO.